Title REVIEW] Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies
Author Brian B. Gowen* and Brady T. Hickerson
Address Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah, 84326, USA
Bibliography Journal of Microbiology, 55(3),183-195, 2017,
DOI 10.1007/s12275-017-7029-8
Key Words bunyavirus, Rift valley fever, severe fever with thrombocytopenia syndrome, Crimean-Congo hemorrhagic fever, hantavirus, antiviral
Abstract A growing number of bunyaviruses are known to cause viral hemorrhagic fever (VHF), a severe febrile illness which can progress to hypovolemic shock and multi-organ failure and is characterized by hematologic abnormalities and vascular leak. At present, there are no approved vaccines or antiviral therapies to effectively prevent or treat VHF caused by pathogenic bunyaviruses. Advances in the modeling of bunyaviral infections have facilitated efforts towards the development of novel post-exposure prophylactic and therapeutic countermeasures, several of which may some day be approved for human use. Here, we review recent progress in animal models of severe bunyaviral infections essential to this mission, as well as promising antivirals and biologicals that are at various stages of the development process.